Literature DB >> 423181

5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline.

G L Tong, D W Henry, E M Acton.   

Abstract

Treatment of daunorubicin with methanolic ammonia affords 5-iminodaunorubicin, the first quinone-modified analogue of either daunorubicin or adriamycin. This product retains antileukemic activity in mice, is less cardiotoxic by electrocardiographic measurements in rats, and is nonmutagenic in Salmonella typhimurium (Ames test).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 423181     DOI: 10.1021/jm00187a009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Comparative effects of doxorubicin and 4'-epi-doxorubicin on nucleic acid metabolism and cytotoxicity in a human tumor cell line.

Authors:  O Cantoni; P Sestili; F Cattabeni; C Geroni; F Giuliani
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.

Authors:  M A Graham; D R Newell; B J Foster; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

4.  Prevention of adriamycin toxicity.

Authors:  A R Banks; T Jones; T H Koch; R D Friedman; N R Bachur
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Effects of 5-iminodaunorubicin on nucleoli of rats.

Authors:  J H Peters; M J Evans; R A Jensen; E M Acton
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.